| New analysis of ACCORD study finds increased mortality with tight glucose control. |
|
| Internal Medicine News: A mean of 3.7 years of intensive glucose-lowering therapy reduced the risk of nonfatal myocardial infarction in patients with advanced type 2 diabetes and a high risk of cardiovascular disease, but increased the risk of death, according to 5-year outcomes from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. |